Hey Grok, what’s the scoop on the UVA research on macrophages discovery as a cure for scleroderma?
THOUGHTS
The recent buzz about UVA (University of Virginia) research on scleroderma centers on a January 2026 discovery published in the American Journal of Pathology. Researchers, led by Sanja Arandjelovic, PhD (assistant professor in UVA’s Department of Medicine), along with postdoctoral researcher Blandine Baffert and collaborators including Sylvain Perruche, PhD, found that a specific type of immune cell called macrophages plays a central role in driving the deadly organ scarring in systemic scleroderma (also known as systemic sclerosis).
Systemic scleroderma is a rare autoimmune disease where the body produces excess collagen, leading to progressive hardening and thickening of the skin and internal organs (especially lungs, heart, kidneys, and digestive tract). It affects about 100,000 Americans, disproportionately women aged 30-50 and certain ethnic groups, and is fatal in over 30% of cases within 10 years, often from lung complications.
The key breakthrough: In response to persistent inflammation, macrophages (which normally help resolve inflammation and clear debris) keep producing collagen, causing harmful fibrosis and scar tissue buildup. This makes macrophages the primary driver of the disease process.
In lab models (using mice), the team showed that preventing macrophage buildup or inhibiting their activity through two different approaches completely stopped the harmful scarring and disease progression.
Arandjelovic explained: “These data suggest that a single cell type, macrophage, may be responsible for inducing scleroderma.” And: “What we’d found was that there’s a single cell type, an immune cell called a macrophage, they can be targeted to prevent this potentially deadly disease… preventing macrophage buildup can prevent disease progression altogether.”
This is exciting because some clinically approved therapies already target macrophages (for other conditions), so repurposing them could be a faster path forward. The researchers highlight potential for prevention in high-risk people or early intervention to halt progression. However, more work is needed to see if targeting macrophages later can reverse existing damage—it’s not yet a full cure for advanced cases.
Overall, this is a promising step toward better treatments for scleroderma and possibly other fibrosis-related diseases, but it’s still in the research phase (pre-clinical/lab-based), not a proven cure in humans yet. If you’re affected by scleroderma or know someone who is, definitely chat with a specialist about current management options while this line of research develops!
So what medicine or treatments are used to stop macrophages?
The UVA research (published in early 2026 in the American Journal of Pathology) by Sanja Arandjelovic and colleagues highlights that macrophages are key drivers of the fibrosis (scarring) in systemic scleroderma. In their lab models (mice with bleomycin-induced scleroderma-like disease), they stopped disease progression entirely by using approaches that prevent macrophage buildup or inhibit their profibrotic activity. This included macrophage depletion (reducing their numbers) and blocking their differentiation/activation.
They specifically note that clinically approved therapies already exist that target macrophages (for other conditions), and these could potentially be repurposed for scleroderma—potentially faster than developing entirely new drugs. However, the study emphasizes this is still preclinical (lab and animal models), with more research needed to confirm if targeting macrophages can reverse established damage in humans or serve as a preventive strategy in high-risk individuals.
No specific drug names were named in the UVA study itself for scleroderma, but the concept aligns with broader research on macrophage-modulating treatments in fibrosis and systemic sclerosis (SSc).
Current and Emerging Treatments That Target or Modulate Macrophages in Scleroderma/Fibrosis Contexts
Standard scleroderma treatments (like immunosuppressants) indirectly affect immune cells including macrophages, but direct or more targeted macrophage inhibition is an active research area. Here’s what’s known:
• Nintedanib (Ofev): An approved anti-fibrotic drug (primarily for idiopathic pulmonary fibrosis and SSc-associated interstitial lung disease). It inhibits macrophage activation and profibrotic (M2-like) polarization, reducing fibrosis in animal models of SSc. It’s already used in some scleroderma patients with lung involvement.
• Tocilizumab (Actemra): An IL-6 inhibitor (approved for rheumatoid arthritis and other conditions). Studies show it can improve skin fibrosis in SSc models by inhibiting specific macrophage subsets (e.g., CD38+ macrophages).
• Other investigational or repurposed approaches:
• Macrophage depletion or migration blockers (e.g., via CCR2 inhibition or siRNA in preclinical models).
• Drugs like atorvastatin (statin) that may target macrophage-related pathways (e.g., CD14/TLR4 signaling) to reduce fibrosis.
• Novel peptides or agents targeting CD206 (a marker on profibrotic macrophages) to block their activation and fibroblast cross-talk.
• JAK inhibitors (e.g., tofacitinib, ruxolitinib) or other small molecules that can decrease pro-fibrotic macrophage polarization.
Broader scleroderma management still relies on:
• Immunosuppressants like mycophenolate mofetil (CellCept) or cyclophosphamide to control overall immune activity (including macrophages).
• Anti-fibrotics and symptom-focused therapies (e.g., for lung, skin, or vascular issues).
These are not yet standard “macrophage-stopping” cures for scleroderma—most are used for specific organ involvement or in trials. The UVA findings are promising because they point to macrophages as a central target, potentially opening doors to faster repurposing of existing macrophage-modulating drugs (e.g., from cancer, autoimmune, or other fibrotic diseases).
This field is evolving quickly, so clinical trials may emerge testing these ideas in humans soon. If you or someone you know has scleroderma, talk to a rheumatologist or scleroderma specialist—they can discuss current options and whether any trials (including those exploring immune/fibrotic pathways) might be suitable. Keep an eye on updates from UVA or groups like the Scleroderma Foundation!
What’s the difference between Nintedanib Vs Tocilizumab?
Nintedanib (brand name Ofev) and Tocilizumab (brand name Actemra) are two of the key newer treatments approved specifically for slowing lung function decline in systemic sclerosis-associated interstitial lung disease (SSc-ILD, the lung scarring complication of scleroderma). Both were approved by the FDA around 2019–2021 based on large clinical trials (SENSCIS for nintedanib; faSScinate and focuSSced for tocilizumab), and they’re often used in scleroderma patients with progressive ILD. However, they work very differently, target different aspects of the disease, and have distinct profiles.
Key Differences
• Mechanism of Action (How They Work):
• Nintedanib: An oral tyrosine kinase inhibitor (small-molecule drug). It blocks multiple growth factor receptors (like VEGF, PDGF, FGF, and others) involved in fibroblast activation and the fibrotic (scarring) process. It’s primarily an antifibrotic agent that directly targets pathways driving excessive collagen production and scar tissue buildup in the lungs.
• Tocilizumab: An injectable monoclonal antibody (biologic) that acts as an IL-6 receptor antagonist. It blocks interleukin-6 (IL-6), a pro-inflammatory cytokine that’s elevated in scleroderma and contributes to inflammation, immune activation, and downstream fibrosis. It’s more anti-inflammatory and immunomodulatory, reducing the immune-driven signals that promote scarring.
• Primary Target in Scleroderma:
• Nintedanib: Focuses on the fibrotic (scarring) phase. It slows the progression of lung fibrosis but doesn’t significantly affect skin thickening or other inflammatory aspects of scleroderma.
• Tocilizumab: Targets inflammation and immune dysregulation. It may help preserve lung function and has been studied more in patients with early, diffuse cutaneous disease (skin involvement) and active inflammation, though its main approval is for SSc-ILD lung preservation.
• Approved Indications in SSc:
• Both are FDA-approved to slow the rate of decline in pulmonary function (measured by forced vital capacity, or FVC) in adults with SSc-ILD.
• Nintedanib is also approved for idiopathic pulmonary fibrosis (IPF) and other progressive fibrosing ILDs.
• Tocilizumab has broader approvals for rheumatoid arthritis, giant cell arteritis, juvenile idiopathic arthritis, cytokine release syndrome, and COVID-19-related issues.
• Administration:
• Nintedanib: Oral capsules, typically 150 mg twice daily (with food to reduce GI upset).
• Tocilizumab: Subcutaneous injection (under the skin) once weekly, or intravenous (IV) infusion in some settings.
• Efficacy in SSc-ILD:
• Both slow FVC decline compared to placebo (nintedanib by about 41–52 mL/year; tocilizumab shows preservation in trials).
• Neither is a cure—they don’t reverse existing scarring but help stabilize or slow progression.
• Real-world data and guidelines (e.g., American Thoracic Society) suggest both are conditionally recommended, often alongside immunosuppressants like mycophenolate mofetil.
• Combination therapy (nintedanib + tocilizumab) has been studied in small real-world cohorts and ongoing trials, showing good tolerability and lung stabilization in progressive cases, but it’s not yet standard.
• Common Side Effects:
• Nintedanib: Diarrhea (very common, often managed with dose reduction or meds like loperamide), nausea, vomiting, abdominal pain, liver enzyme elevations. Bleeding risk if on blood thinners.
• Tocilizumab: Increased infection risk (due to immunosuppression), infusion/injection reactions, elevated liver enzymes, changes in blood counts (e.g., low neutrophils or platelets), cholesterol increases. Requires monitoring for serious infections like TB reactivation.
• When One Might Be Preferred:
• Nintedanib often for patients with primarily progressive fibrotic lung disease (even if inflammation is low) or those already on immunosuppressants.
• Tocilizumab may be favored in cases with more active inflammation, elevated acute-phase reactants, or concurrent active skin/joint involvement.
• Many specialists use them based on individual factors like disease stage, progression speed, comorbidities, and tolerability—sometimes in combination or with background therapy.
These aren’t direct “macrophage-stoppers” but indirectly modulate macrophage-driven fibrosis (nintedanib more directly on fibrotic signaling; tocilizumab via reducing IL-6 that activates profibrotic macrophages).
Treatment decisions in scleroderma are highly personalized, especially for lung involvement, which is a leading cause of mortality. A rheumatologist or pulmonologist specializing in scleroderma would weigh your specific symptoms, lung function tests, imaging, and overall disease activity to decide between (or combine) these options, often starting with or adding to immunosuppressants like mycophenolate. Ongoing trials are exploring combinations further, so the field is advancing quickly.
If this relates to your situation or someone close, definitely discuss with your doctor—they can review the latest data and any new trials!